Adoptive Therapy with CAR T Cells
Sunday, April 30
2:00 - 5:00 PM
Course Overview:
Adoptive cell therapy for the treatment of advanced hematological and solid malignancies started two decades ago by demonstration of cancer cell-specific lysis by tumor-directed immune cells. Increasing successes in the treatment of CD19-positive hematological malignancies by chimeric antigen receptor (CAR) T-cell therapy and in melanoma by T-cell receptor (TCR)-engineered T cells underscore the potential to extend similar strategies to other malignancies. Advances in understanding of tumor immunology, T-cell costimulatory and coinhibitory signaling, tumor immunology and checkpoint blockade provided opportunity to develop combination therapy strategies that are now being translated to the clinic. The course objective is to provide the basics of adoptive cell therapy and insights into the translational developments.
Course Agenda
2:00 The ABC of CARs
Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
2:30 CAR T-Cell Therapy for CD19 Positive Hematological Malignancies
Matthew J. Frigault, M.D., Clinical Fellow in Medicine, Dana-Farber Cancer Institute
3:00 CAR T-Cell Therapy for Non-CD19 Hematological Malignancies
Eric L. Smith, M.D., Ph.D., Assistant Attending, Myeloma Service; Director of Clinical Translation, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center
4:00 CAR T-Cell Therapy for Solid Tumors
Carl J DeSelm, M.D., Ph.D., Researcher, Immunotherapy, Memorial Sloan Kettering Cancer Center
4:30 Combination Immunotherapies
Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
5:00 Close of Course
Instructors:
Prasad S. Adusumilli, M.D., F.A.C.S., Associate Attending and Deputy Chief, Thoracic Surgery, Memorial Sloan Kettering Cancer Center
Prasad S Adusumilli MD, FACS is Deputy Chief and Associate Attending in Thoracic Surgery and a Member of the Center for Cell Engineering and Experimental Therapeutics Center at Memorial Sloan Kettering Cancer Center (MSK) in New York. Dr. Adusumilli research focuses on tumor immunology and CAR T-cell immunotherapy for thoracic cancers, specifically non-small cell lung cancer, pleural mesothelioma, and breast cancer. Mesothelin-targeted CAR T cells developed in the laboratory are now in two phase I clinical trials. Dr. Adusumilli’s research has been funded by a multitude of federal agencies and private foundations that include: The National Cancer Institute, the Department of Defense, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer. Laboratory research has been published in Science Translational Medicine, Journal of Clinical Investigation, Journal Clinical Oncology, Journal of The National Cancer Institute, FASEB, Cancer Discovery, and Clinical Cancer Research.
Carl J DeSelm, M.D., Ph.D., Researcher, Immunotherapy, Memorial Sloan Kettering Cancer Center
Matthew J. Frigault, M.D., Clinical Fellow in Medicine, Dana-Farber Cancer Institute
Eric L. Smith, M.D., Ph.D., Assistant Attending, Myeloma Service; Director of Clinical Translation, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center